Cometriq (cabozantinib)
An approved treatment for Medullary Thyroid Cancer and Familial Medullary Thyroid Carcinoma.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify Cabozantinib wherever you encounter it, plus the key facts at a glance.
- Generic name
- Cabozantinib
- Brand name
- Cometriq
- Development code
- XL184
- Drug class
- Multi-kinase inhibitor
- Manufacturer
- Exelixis
- How it's taken
- Oral capsule, once a day on an empty stomach
A once-daily capsule for medullary thyroid cancer that is progressive, meaning growing, and metastatic, meaning it has spread[1].
- The FDA approved Cometriq on November 29, 2012[2].
- The current Cometriq label has no boxed warning, and its warnings include tears and abnormal openings in the gut and airway, serious bleeding, blood clots and heart failure[1].
- Cometriq capsules contain the same medicine as Cabometyx tablets, and the Cometriq label says not to substitute Cometriq capsules with cabozantinib tablets[1][4].
We'll email you when Cometriq's FDA label changes, when the FDA acts on it, and when new trials for the condition you pick open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where Cabozantinib fits
Cometriq (cabozantinib) is a once-daily capsule approved since 2012 for progressive, metastatic medullary thyroid cancer, and its label does not require a RET mutation[1][2].
- Caprelsa (vandetanib) is the other multi-kinase inhibitor approved for medullary thyroid cancer, for cancer that is causing symptoms or growing and cannot be removed by surgery or has spread[8].
- Retevmo (selpercatinib) is approved for advanced or metastatic medullary thyroid cancer with a RET mutation in adults and children 2 and older[9].
- Gavreto (pralsetinib) no longer has a medullary thyroid cancer use, because the FDA removed that accelerated approval indication on July 20, 2023 at Genentech's request[10]. Neither the Cometriq nor the Caprelsa label reports a trial comparing the 2 drugs directly.
- In medullary thyroid cancer, the LIBRETTO-531 trial compared Retevmo with a doctor's choice of cabozantinib or vandetanib in people who had not taken a kinase inhibitor, and progression-free survival was longer on Retevmo (hazard ratio 0.28)[9].
- Cabometyx tablets contain the same medicine as Cometriq, but the Cabometyx label does not cover medullary thyroid cancer and the Cometriq label says the 2 forms are not substituted for each other[4][1].
- Anyone weighing Cometriq can ask their oncologist whether the cancer carries a RET mutation and how the empty-stomach dosing and blood pressure checks would fit their routine.
How Cabozantinib works
In laboratory tests, cabozantinib blocks the tyrosine kinase activity of RET, MET, the VEGF receptors 1, 2 and 3, KIT, TRKB, FLT-3, AXL, ROS1, TYRO3, MER and TIE-2[1]. The Cometriq label says these kinases take part in cancer growth and spread, in the growth of new blood vessels that feed tumors and in drug resistance[1]. The Cometriq label does not require a RET test before treatment, and in its main trial the RET result was positive in 51% of patients, negative in 14% and unknown in 35%[1].
Side effects and safety
- Perforations and fistulas. tears in the gut in 3% and abnormal openings (fistulas) from the gut in 1%, plus fistulas outside the gut, including fistulas of the windpipe or food pipe, in 4%, some fatal; Cometriq is stopped for a gut tear or a grade 4 fistula
- Serious bleeding. severe and fatal bleeding occurred; grade 3 or worse in 3% against 1% on placebo; not given after recent bleeding, such as coughing up or vomiting blood or black stools
- Blood clots. clots in veins in 6% against 3% on placebo and in arteries in 2% against 0%; stopped for a heart attack or a clot that needs treatment
- Slow wound healing. held at least 3 weeks before planned surgery and for at least 2 weeks after major surgery until the wound heals
- High blood pressure. stage 1 or 2 high blood pressure in 61% against 30% on placebo; not started when blood pressure is uncontrolled, and stopped for a hypertensive crisis
- Heart failure. a warning the label lists as changed in October 2025; can cause severe and fatal heart failure; heart failure occurred in 0.9% of people taking Cometriq alone, with a median onset at 76 days
- Osteonecrosis of the jaw. in 1%; an oral exam before and during treatment, and Cometriq is held at least 3 weeks before dental surgery or invasive dental work
- Diarrhea. in 63%, grade 3 or 4 in 16%
- Hand-foot syndrome (palmar-plantar erythrodysesthesia). in 50%, grade 3 in 13%
- Protein in the urine. in 2%, including 1 person with nephrotic syndrome; Cometriq is stopped for nephrotic syndrome
- Reversible posterior leukoencephalopathy syndrome (RPLS). brain swelling seen on MRI, with seizures, headache, vision changes or confusion; occurred in 1 person (less than 1%)
- Low blood calcium. in 52%, grade 3 or 4 in 12%; calcium is checked and replaced as needed
- Pregnancy and breastfeeding. can harm an unborn baby; pregnancy status is checked before starting, effective contraception during treatment and for 4 months after the last dose, and no breastfeeding for the same time
- Blood pressure, regularly throughout treatment
- Urine protein, regularly
- Blood calcium, with replacement as needed
- An oral exam before starting and from time to time during treatment
- Heart pumping function (left ventricular ejection fraction), which the label says to consider at the start and from time to time
- A pregnancy test before starting, for anyone who could become pregnant
The current Cometriq label has no boxed warning[1]. Its warnings cover tears in the gut (3%) and fistulas, abnormal openings from the gut (1%) or outside the gut, such as between the windpipe and the food pipe (4%), some of them fatal; severe and fatal bleeding; blood clots in veins (6% against 3% on placebo) and arteries (2% against 0%); slow wound healing; high blood pressure, including hypertensive crisis; heart failure, a warning the label lists as changed in October 2025; osteonecrosis of the jaw (1%); severe diarrhea; hand-foot syndrome; protein in the urine; a brain swelling syndrome called RPLS; low blood calcium; and harm to an unborn baby[1].
In the main trial of 214 people on Cometriq and 109 on placebo, the most common side effects were diarrhea (63% against 33%), mouth sores (51% against 6%), hand-foot syndrome (50% against 2%), weight loss (48% against 10%), decreased appetite (46% against 16%), nausea (43% against 21%), fatigue (41% against 28%), mouth pain (36% against 6%), hair color changes (34% against 1%), changes in taste (34% against 6%), high blood pressure (33% against 4%), abdominal pain (27% against 13%) and constipation (27% against 6%)[1].
Lab changes included raised liver enzymes AST and ALT (86% each, against 35% and 41%), low calcium (52% against 27%), low lymphocytes, a kind of white blood cell (53% against 51%), and low platelets (35% against 4%)[1]. The dose was lowered in 79% of people on Cometriq, against 9% on placebo, and side effects led 16% to stop Cometriq[1].
Side effects that led to death occurred in 6% on Cometriq, from bleeding, pneumonia, blood infection, fistulas, cardiac arrest, respiratory failure and unspecified causes, against 5% on placebo[1]. The label also reports that TSH, the thyroid-stimulating hormone, rose in 57% on Cometriq against 19% on placebo; in the trial, 92% of people on Cometriq had already had their thyroid removed[1]. Since approval, aneurysms, dissections and ruptures of arteries, including the aorta, have been reported[1].
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Cabozantinib
The dose is 140mg by mouth once a day, until the cancer grows or side effects become too much[1]. Cometriq is taken without food: no eating for at least 2 hours before and at least 1 hour after each dose[1]. Capsules are swallowed whole and not opened, and a missed dose is not taken within 12 hours of the next one[1]. The label says not to substitute Cometriq capsules with cabozantinib tablets[1].
For serious or intolerable side effects, Cometriq is paused and restarted at 100mg, then 60mg[1]. People with mild or moderate liver impairment start at 80mg, and the label does not recommend Cometriq with severe liver impairment; no dose change is needed for mild or moderate kidney impairment[1].
The label says to avoid strong CYP3A4 inhibitors, such as ketoconazole, itraconazole and clarithromycin, or lower the dose by 40mg, and to avoid strong CYP3A4 inducers, such as rifampin, phenytoin, carbamazepine and St. John's wort, or raise the dose by 40mg, to no more than 180mg a day[1]. Grapefruit, grapefruit juice and supplements known to block cytochrome P450 enzymes are also avoided[1]. Cometriq comes as 20mg and 80mg capsules packed in cartons for daily doses of 140mg, 100mg or 60mg[1].
Availability and cost
Only available as the brand-name product.
A daily oral cancer drug. The label gives no price. Drugs@FDA lists no generic cabozantinib capsules; the generic cabozantinib approvals are tablets made to match Cabometyx, which the Cometriq label says are not substituted for Cometriq capsules[1][5]. Omcazio, a different cabozantinib capsule approved on September 3, 2026, is approved for other cancers, not medullary thyroid cancer, and its label says it is not substitutable mg-to-mg with other cabozantinib products[6]. Exelixis Access Services offers a co-pay program for commercially insured patients and free drug for some people who qualify.
Help paying for Cometriq
With private insurance, the drugmaker's copay card can lower what you pay for Cometriq. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. None of the 3 charity funds for the conditions it treats were open on November 16, 2026. Without insurance, you can apply to the drugmaker's free medicine program, which sets its own eligibility rules. Pick your insurance below to see which offers fit you.
- Copay help
EASE Co-Pay Program: eligible commercially insured patients may pay as little as $0 per month. Annual and transaction limits apply but are not stated on the page. Not available to patients with federal, state or other government-funded insurance.
For: private insurance · source - Free medicine program
EASE Patient Assistance Program: may provide Cometriq free of charge to patients who are uninsured or cannot afford their medicine and who qualify. Additional restrictions and eligibility rules apply; no income limit is published.
For: no insurance · source - Insurance and case manager help
EASE answers questions on financial assistance for Cometriq at 1-844-900-EASE (1-844-900-3273), 8:00 AM to 8:00 PM ET, Monday to Friday. Forms are faxed to 1-844-901-3273.
The official page does not say who qualifies. Ask the program. · source
Good to know: Read on cometriq.com/support on November 15, 2026. No co-pay maximum, income limit, bridge supply or specialty pharmacy is published.
Charity funds
- From a charity · The Assistance FundThyroid Cancer fundWaitlist
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
Every program and charity fund for Medullary Thyroid Cancer →
Every program and charity fund for Familial Medullary Thyroid Carcinoma →
Access and eligibility
Approved for progressive, metastatic medullary thyroid cancer[1]. The label does not separate inherited from non-inherited medullary thyroid cancer and does not require a RET test. Safety and effectiveness in children have not been studied, and the main trial did not include enough people 65 and older to tell whether they respond differently[1]. The label does not recommend Cometriq with severe liver impairment and has no experience with severe kidney impairment[1].
Source: Exelixis Access Services
Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.
Clinical trial results
The pivotal trial, EXAM (NCT00704730), randomized 330 people with metastatic medullary thyroid cancer that had grown within the 14 months before joining, 2 to 1, to Cometriq 140mg (219) or placebo (111)[1][7]. Cometriq lengthened progression-free survival, the time before the cancer grew: the median was 11.2 months on Cometriq against 4.0 months on placebo (hazard ratio 0.28)[1].
Tumors shrank in 27% on Cometriq, all partial responses, against 0% on placebo, and the responses lasted a median of 14.7 months[1]. Overall survival was not significantly different, with medians of 26.6 months on Cometriq and 21.1 months on placebo (hazard ratio 0.85)[1]. The trial did not let placebo patients switch to Cometriq when their cancer grew[1].
In the trial, 92% had already had thyroid surgery, 21% had taken a kinase inhibitor before and 25% had taken 2 or more earlier treatments[1]. Cabozantinib was later a comparator in LIBRETTO-531 (NCT04211337), where people with RET-mutant medullary thyroid cancer who had not taken a kinase inhibitor got Retevmo or a doctor's choice of cabozantinib or vandetanib[9].
Development history
Exelixis developed cabozantinib under the code XL184, which is still printed on Cometriq capsules[1][7]. The EXAM trial began in June 2008[7]. The FDA approved Cometriq on November 29, 2012 under NDA 203756, after a priority review, and Drugs@FDA lists the application as an orphan drug and a new molecular entity[2][3]. The FDA approved cabozantinib tablets under a separate application, as Cabometyx, on April 25, 2016, and the Cabometyx label covers other cancers, not medullary thyroid cancer[5][4].
The Cometriq label updated in October 2025 lists a change to its heart failure warning[1].
Explore Medullary Thyroid Cancer and Familial Medullary Thyroid Carcinoma trials
Other Medullary Thyroid Cancer & Familial Medullary Thyroid Carcinoma treatments
Common questions about Cabozantinib
▸What is Cabozantinib (Cometriq)?
A once-daily capsule for medullary thyroid cancer that is progressive, meaning growing, and metastatic, meaning it has spread[1]. The FDA approved Cometriq on November 29, 2012[2]. The current Cometriq label has no boxed warning, and its warnings include tears and abnormal openings in the gut and airway, serious bleeding, blood clots and heart failure[1]. Cometriq capsules contain the same medicine as Cabometyx tablets, and the Cometriq label says not to substitute Cometriq capsules with cabozantinib tablets[1][4].
▸How does Cabozantinib work?
In laboratory tests, cabozantinib blocks the tyrosine kinase activity of RET, MET, the VEGF receptors 1, 2 and 3, KIT, TRKB, FLT-3, AXL, ROS1, TYRO3, MER and TIE-2[1]. The Cometriq label says these kinases take part in cancer growth and spread, in the growth of new blood vessels that feed tumors and in drug resistance[1]. The Cometriq label does not require a RET test before treatment, and in its main trial the RET result was positive in 51% of patients, negative in 14% and unknown in 35%[1].
▸What are the side effects of Cabozantinib?
The current Cometriq label has no boxed warning[1]. Its warnings cover tears in the gut (3%) and fistulas, abnormal openings from the gut (1%) or outside the gut, such as between the windpipe and the food pipe (4%), some of them fatal; severe and fatal bleeding; blood clots in veins (6% against 3% on placebo) and arteries (2% against 0%); slow wound healing; high blood pressure, including hypertensive crisis; heart failure, a warning the label lists as changed in October 2025; osteonecrosis of the jaw (1%); severe diarrhea; hand-foot syndrome; protein in the urine; a brain swelling syndrome called RPLS; low blood calcium; and harm to an unborn baby[1]. In the main trial of 214 people on Cometriq and 109 on placebo, the most common side effects were diarrhea (63% against 33%), mouth sores (51% against 6%), hand-foot syndrome (50% against 2%), weight loss (48% against 10%), decreased appetite (46% against 16%), nausea (43% against 21%), fatigue (41% against 28%), mouth pain (36% against 6%), hair color changes (34% against 1%), changes in taste (34% against 6%), high blood pressure (33% against 4%), abdominal pain (27% against 13%) and constipation (27% against 6%)[1]. Lab changes included raised liver enzymes AST and ALT (86% each, against 35% and 41%), low calcium (52% against 27%), low lymphocytes, a kind of white blood cell (53% against 51%), and low platelets (35% against 4%)[1]. The dose was lowered in 79% of people on Cometriq, against 9% on placebo, and side effects led 16% to stop Cometriq[1]. Side effects that led to death occurred in 6% on Cometriq, from bleeding, pneumonia, blood infection, fistulas, cardiac arrest, respiratory failure and unspecified causes, against 5% on placebo[1]. The label also reports that TSH, the thyroid-stimulating hormone, rose in 57% on Cometriq against 19% on placebo; in the trial, 92% of people on Cometriq had already had their thyroid removed[1]. Since approval, aneurysms, dissections and ruptures of arteries, including the aorta, have been reported[1].
▸How is Cabozantinib taken?
The dose is 140mg by mouth once a day, until the cancer grows or side effects become too much[1]. Cometriq is taken without food: no eating for at least 2 hours before and at least 1 hour after each dose[1]. Capsules are swallowed whole and not opened, and a missed dose is not taken within 12 hours of the next one[1]. The label says not to substitute Cometriq capsules with cabozantinib tablets[1]. For serious or intolerable side effects, Cometriq is paused and restarted at 100mg, then 60mg[1]. People with mild or moderate liver impairment start at 80mg, and the label does not recommend Cometriq with severe liver impairment; no dose change is needed for mild or moderate kidney impairment[1]. The label says to avoid strong CYP3A4 inhibitors, such as ketoconazole, itraconazole and clarithromycin, or lower the dose by 40mg, and to avoid strong CYP3A4 inducers, such as rifampin, phenytoin, carbamazepine and St. John's wort, or raise the dose by 40mg, to no more than 180mg a day[1]. Grapefruit, grapefruit juice and supplements known to block cytochrome P450 enzymes are also avoided[1]. Cometriq comes as 20mg and 80mg capsules packed in cartons for daily doses of 140mg, 100mg or 60mg[1].
▸Is Cabozantinib FDA approved?
Yes. The FDA approved Cometriq on November 29, 2012 for progressive, metastatic medullary thyroid cancer.
Hereditary or not: the label's indication does not separate inherited from non-inherited medullary thyroid cancer and does not require a RET test.
Capsules only: the label says not to substitute Cometriq capsules with cabozantinib tablets such as Cabometyx.
Children: safety and effectiveness have not been studied.
Source: Cometriq prescribing information
▸Is Cometriq the same as Cabometyx?
Both contain cabozantinib, but they are different products with different approved uses, and the Cometriq label says not to substitute Cometriq capsules with cabozantinib tablets[1].
Cometriq: capsules, 140mg once a day, approved for progressive, metastatic medullary thyroid cancer.
Cabometyx: tablets approved for kidney cancer, liver cancer, differentiated thyroid cancer and some neuroendocrine tumors, not medullary thyroid cancer.
Food: Cometriq is taken with no food for 2 hours before and 1 hour after each dose.
Source: Cometriq prescribing information and Cabometyx prescribing information
▸How do you take Cometriq?
The label dose is 140mg by mouth once a day on an empty stomach[1].
Food: no eating for at least 2 hours before and at least 1 hour after each dose.
Capsules: swallowed whole and never opened.
Missed dose: not taken within 12 hours of the next dose.
Foods: the label says to avoid grapefruit, grapefruit juice and supplements that block cytochrome P450 enzymes.
Liver: people with mild or moderate liver impairment start at 80mg.
Source: Cometriq prescribing information
▸How well did Cometriq work for medullary thyroid cancer?
In the EXAM trial of 330 people, Cometriq delayed cancer growth: median progression-free survival was 11.2 months against 4.0 months on placebo (hazard ratio 0.28)[1].
Tumor shrinkage: 27% on Cometriq, all partial responses, against 0% on placebo.
How long: responses lasted a median of 14.7 months.
Overall survival: not significantly different, with medians of 26.6 and 21.1 months.
Source: Cometriq prescribing information
▸Is there help paying for Cometriq?
Exelixis Access Services (EASE) offers a co-pay program and a patient assistance program for Cometriq[11].
Co-pay: eligible commercially insured patients may pay as little as $0 a month, with annual and transaction limits.
Not eligible for co-pay help: people with federal, state or other government-funded insurance.
Free drug: the patient assistance program may give Cometriq free to people who qualify; the page lists no income limit.
Phone: 1-844-900-3273, 8AM to 8PM ET, Monday to Friday.
Source: Exelixis Access Services
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- Exelixis, Inc. via DailyMed · 2025-10-18. COMETRIQ- cabozantinib kit / COMETRIQ- cabozantinib capsule. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a0c3bea-c87b-4d25-bb44-5f0174da6b34
- U.S. Food and Drug Administration · 2012-11-29. COMETRIQ approval history, NDA 203756. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203756
- U.S. Food and Drug Administration · 2012-11-29. NDA 203756 approval letter (COMETRIQ). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/203756Orig1s000ltr.pdf
- Exelixis, Inc. via DailyMed · 2025-10-19. CABOMETYX- cabozantinib tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3850cce2-6137-42e5-a792-d318c4a4b3b5
- U.S. Food and Drug Administration · 2016-04-25. CABOMETYX approval history, NDA 208692. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208692
- U.S. Food and Drug Administration · 2026-09-03. OMCAZIO approval history, NDA 220613. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220613
- ClinicalTrials.gov. Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer. https://clinicaltrials.gov/study/NCT00704730
- Genzyme Corporation via DailyMed · 2026-10-30. CAPRELSA- vandetanib tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5721cb8-4185-47b9-bbb3-1c587e558a03
- Eli Lilly and Company via DailyMed · 2026-09-11. RETEVMO- selpercatinib capsule RETEVMO- selpercatinib tablet, coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fa848ba-a59c-4144-9f52-64d090f4d828
- U.S. Food and Drug Administration · 2023-07-20. NDA 213721/S-014 supplement approval, withdrawal of accelerated approval indication (GAVRETO). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/213721Orig1s014ltr.pdf
- Exelixis. Exelixis Access Services | COMETRIQ® (cabozantinib). https://www.cometriq.com/support